Transcatheter arterial chemoembolization plus lenvatinib toward precision prognostication for unresectable hepatocellular carcinoma

doi:10.4251/wjgo.v18.i6.116250

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 6

This Article

(1)

(0)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Opinion Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Jun 15, 2026; 18(6): 116250
Published online Jun 15, 2026. doi: 10.4251/wjgo.v18.i6.116250

Transcatheter arterial chemoembolization plus lenvatinib toward precision prognostication for unresectable hepatocellular carcinoma

Yu-Han Yang

Yu-Han Yang, West China Hospital, Sichuan University, Chengdu 6100041, Sichuan Province, China

Author contributions: Yang YH was responsible for conceptualization, writing the original draft, and reviewing and editing the manuscript, read and approved the final manuscript and agree to be accountable for all aspects of the work.

AI contribution statement: No use of AI tools for the manuscript.

Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Corresponding author: Yu-Han Yang, Assistant Professor, West China Hospital, Sichuan University, No. 17 People’s South Road, Chengdu 6100041, Sichuan Province, China. yyh_1023@163.com

Received: November 6, 2025
Revised: January 2, 2026
Accepted: February 4, 2026
Published online: June 15, 2026
Processing time: 215 Days and 11.5 Hours

Core Tip

Core Tip: We summarized risk factors including number of tumors, microvascular invasion, Eastern Cooperative Oncology Group performance status, and Child-Pugh stage, and protective factor (triple therapy) for unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus lenvatinib, constructed and validated prognostic models. In the validation set, area under the curve values of overall survival and progression-free survival, calibration curves, confirmed their good performance, providing guidance for clinical practice.